What is the main reason for this 8-K filing?

The primary reason for this filing is to disclose the voluntary removal of Boston Scientific's high voltage ICD and CRT-D devices and to announce conference calls with physicians discussing this action and updates on the Cardiology, Rhythm and Vascular business.

Where can I find more details about the device removal?

More detailed information regarding the voluntary removal of the devices and the accompanying physician communications is available in Exhibit 99.1, which is the script for the March 29, 2010, physician conference calls, furnished with this 8-K filing.

What is Regulation FD Disclosure?

Regulation FD (Fair Disclosure) is an SEC rule that requires public companies to disclose material non-public information to the public in a broad and non-exclusionary manner. This filing under Item 7.01 indicates that the company is making information available to all investors simultaneously.

Does this filing provide financial information or impact estimates?

This specific 8-K filing does not provide detailed financial statements or estimates of the impact of the device removal. The core purpose is to inform about the event and the communication plan with physicians. Investors will need to refer to the furnished script and future SEC filings for any potential financial implications.

BSX 8-K: Regulation FD — Mar 29, 2010

Summary

Boston Scientific Corporation (BSX) filed an 8-K on March 29, 2010, primarily to disclose information regarding a voluntary removal of its high voltage Implantable Cardioverter-Defibrillator (ICD) and Cardiac Resynchronization Therapy Defibrillator (CRT-D) devices. The company is hosting conference calls with physicians to discuss this removal and to provide an update on its new Cardiology, Rhythm and Vascular business. Investors should note that the specific details of the device removal and its potential impact on the company's financial performance and market position are likely to be elaborated in the furnished script (Exhibit 99.1). This filing serves as a Regulation FD disclosure, ensuring that material information is disseminated broadly to the public. While the 8-K itself is brief, the accompanying script is critical for understanding the nature and scope of the device removal, the reasons behind it, and any corrective actions or communications being made to healthcare professionals. Investors are advised to review the furnished script for a comprehensive understanding of the situation.

Key Highlights

1Voluntary removal of high voltage ICD and CRT-D devices by Boston Scientific.
2Company hosting conference calls with physicians on March 29, 2010, to discuss the device removal.
3Update on the new Cardiology, Rhythm and Vascular business also on the agenda for the calls.
4Filing is made under Regulation FD Disclosure (Item 7.01).
5A script for the physician conference calls is furnished as Exhibit 99.1.
6The SEC filing date is March 29, 2010, with the earliest event date also being March 29, 2010.

BOSTON SCIENTIFIC CORP 8-K Report, Regulation FD Disclosure (Mar 29, 2010)

Summary

Key Highlights

Frequently Asked Questions